PURPOSE: Spindle cell oncocytomas (SCOs) are very rare tumors of the posterior pituitary with potential for locally aggressive behaviour. Their treatment includes surgery and possibly radiotherapy, however other options are lacking. Somatostatin receptors (SSTs) are a possible therapeutic target for somatostatin analogues and their expression has been demonstrated recently in closely related pituicytomas, but there are no data about their presence in SCOs. METHODS: We collected five cases of SCO from four patients including one recurrent case. Immunohistochemical detection of TTF1, GFAP, CD68, SST1, SST2, SST3, SST5 and D2 dopamine receptor (D2DR) was performed. Intensity, percentage of positive cells and pattern of expression was evaluated in semiquantitative fashion. Protein expression of SST1-5 and D2DR was further evaluated by western blot. RESULTS: Mean patient age was 61.8 years (range 47-71 years) with male to female ratio 1:1. In one patient, samples from the original tumor and its recurrence 16 years later were assessed. TTF1 was positive in all five cases, no expression of GFAP and CD68 was seen. Immunohistochemical expression of SST1 was noted in 1/5 cases, SST2 in 2/5 cases, including recurrent case but not the original case. SST3 was expressed in 3/5 tumors and D2 dopamine receptor in 4/5 cases. Western blot was successfully performed in four samples. SST2, SST3 and D2DR expression was identified in all the samples, including two cases originally negative for SST2 and one case negative for SST3 by immunohistochemistry. The number of positive cells and level of expression varied among different areas of the same tumors. No expression of SST5 was observed. In the patient with the recurrent tumor, intensity of SST2, SST3 and D2DR expression varied between original tumor and its recurrence. CONCLUSIONS: We demonstrated presence of different SST subtypes and D2DR in spindle cell oncocytomas. The most commonly expressed subtype was SST2 and SST3, while no expression of SST5 was observed. Expression showed spatial heterogeneity and temporal changes as seen in the recurrent case. The biological meaning of SSTs expression in SCOs is unclear as well as whether it may be exploited in treatment of selected cases.

4th Department of Internal Medicine University Hospital and Faculty of Medicine Hradec Kralove Charles University Sokolska 581 500 05 Hradec Kralove Czech Republic

Cytopathos s r o Kutuzovova 255 23 831 03 Bratislava Slovakia

Department of Medical Biology and Genetics Faculty of Medicine Hradec Kralove Charles University Simkova 870 500 03 Hradec Kralove Czech Republic

Pathology Department Na Homolce Hospital Roentgenova 2 150 30 Prague 5 Prague Czech Republic

The Fingerland Department of Pathology University Hospital and Faculty of Medicine Hradec Kralove Charles University Sokolska 581 500 05 Hradec Kralove Czech Republic

Zobrazit více v PubMed

J Endocrinol Invest. 2001 Jun;24(6):430-7 PubMed

Endocrine. 2001 Apr;14(3):329-36 PubMed

Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2193-201 PubMed

J Cell Sci. 2001 Oct;114(Pt 19):3517-27 PubMed

Am J Surg Pathol. 2002 Aug;26(8):1048-55 PubMed

J Clin Pathol. 2004 Feb;57(2):168-71 PubMed

J Pathol. 2007 Feb;211(3):370-8 PubMed

Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74 PubMed

J Clin Endocrinol Metab. 2009 Feb;94(2):654-61 PubMed

Mol Cell Endocrinol. 2010 Sep 15;326(1-2):89-98 PubMed

J Med Case Rep. 2011 Feb 14;5:64 PubMed

Am J Surg Pathol. 2012 Feb;36(2):242-52 PubMed

Neuroendocrinology. 2012;96(4):301-10 PubMed

J Mol Signal. 2012 May 31;7(1):5 PubMed

Onco Targets Ther. 2013 Apr 26;6:471-83 PubMed

Front Neuroendocrinol. 2013 Aug;34(3):228-52 PubMed

Am J Surg Pathol. 2013 Nov;37(11):1694-9 PubMed

J Clin Endocrinol Metab. 2013 Nov;98(11):E1730-9 PubMed

J Exp Clin Cancer Res. 2014 Jul 16;33:56 PubMed

Braz J Med Biol Res. 2015 May;48(5):415-9 PubMed

Eur J Endocrinol. 2016 Jul;175(1):63-72 PubMed

Endocr Relat Cancer. 2016 Dec;23(12):R551-R566 PubMed

CNS Neurosci Ther. 2017 Jul;23(7):620-626 PubMed

Neuropathology. 2017 Dec;37(6):535-543 PubMed

Pharmacol Rev. 2018 Oct;70(4):763-835 PubMed